William H. Carson net worth and biography

William Carson Biography and Net Worth

Director of Annexon

Dr. Carson has served as the Chairman of the Board of Otsuka Pharmaceutical Development & Commercialization, Inc., since January 2020. From 2010 to 2019, Dr. Carson served as president and CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. Under his leadership, Dr. Carson brought several products to market, including the first digital medicine approved by the FDA, Abilify Mycite^® (aripiprazole tablets with sensor).

Dr. Carson is a board member of Excision Biotherapeutics, Saama Technologies and Internet2, and is an advisor to Artis Ventures, a venture capital firm that focuses on health and technology innovations. He previously served on the board of Prevail Therapeutics, which was acquired by Eli Lilly. Dr. Carson is also chairman of the Sozosei Foundation, the philanthropic arm of Otsuka America Pharmaceutical, Inc., and Board Chair Emeritus of the Sphinx Organization, which is dedicated to diversity in the arts. He holds a Bachelor of Arts in History and Science from Harvard College and completed his medical degree from Case Western Reserve University School of Medicine, followed by his residency in psychiatry at Tufts / New England Medical Center. He was on faculty at the Medical University of South Carolina in the Department of Psychiatry and Behavioral Sciences from 1988 to 1998 before joining the pharmaceutical industry in 1998 in the Pharmaceutical Research Institute at Bristol-Myers Squibb. He then joined Otsuka in 2002.

What is William H. Carson's net worth?: The estimated net worth of William H. Carson is at least $225.80 thousand as of December 1st, 2025. Carson owns 50,290 shares of Annexon stock worth more than $225,802 as of December 4th. This net worth approximation does not reflect any other assets that Carson may own. Learn More about William H. Carson's net worth.
How do I contact William H. Carson?: The corporate mailing address for Carson and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at [email protected]. Learn More on William H. Carson's contact information.
Has William H. Carson been buying or selling shares of Annexon?: During the past quarter, William H. Carson has bought $31,438.60 in shares of Annexon stock. Most recently, on Monday, December 1st, William H. Carson bought 4,115 shares of Annexon stock. The stock was acquired at an average cost of $4.47 per share, with a total value of $18,394.05. Following the completion of the transaction, the director now directly owns 50,290 shares of the company's stock, valued at $224,796.30. Learn More on William H. Carson's trading history.
Who are Annexon's active insiders?: Annexon's insider roster includes Dean Artis (EVP), William Carson (Director), Jamie Dananberg (Insider), Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), Michael Overdorf (EVP), Muneer Satter (Director), and Ted Yednock (EVP). Learn More on Annexon's active insiders.
Are insiders buying or selling shares of Annexon?: During the last twelve months, Annexon insiders bought shares 10 times. They purchased a total of 1,876,188 shares worth more than $7,268,165.34. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 32,352 shares worth more than $93,274.67. The most recent insider tranaction occured on December, 1st when Director Jung Choi bought 33,000 shares worth more than $138,270.00. Insiders at Annexon own 11.9% of the company. Learn More about insider trades at Annexon.
Information on this page was last updated on 12/1/2025.

William H. Carson Insider Trading History at Annexon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2025	Buy	4,115	$4.47	$18,394.05	50,290
10/30/2025	Buy	4,115	$3.17	$13,044.55	46,175
9/30/2025	Buy	4,115	$3.05	$12,550.75	42,060
7/30/2025	Buy	4,115	$2.43	$9,999.45	33,830
6/30/2025	Buy	4,115	$2.46	$10,122.90	29,715
12/2/2024	Buy	3,200	$5.33	$17,056.00	25,600
9/3/2024	Buy	3,200	$5.48	$17,536.00	19,200
8/1/2024	Buy	3,200	$6.24	$19,968.00	16,000
7/1/2024	Buy	3,200	$5.00	$16,000.00	12,800
4/8/2024	Buy	3,200	$6.07	$19,424.00	3,200

William H. Carson Buying and Selling Activity at Annexon

Annexon Company Overview

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Today's Range

Now: $4.49

$4.25

$4.55

50 Day Range

MA: $3.38

$2.68

$4.51

2 Week Range

Now: $4.49

$1.28

$5.66

Volume

2,488,278 shs

Average Volume

3,148,846 shs

Market Capitalization

$537.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2